help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, N. N.
Right arrow Articles by Termine, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, N. N.
Right arrow Articles by Termine, J. D.

Endocrinology, Vol 137, 2075-2084, Copyright © 1996 by Endocrine Society

ARTICLES

Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance

NN Yang, HU Bryant, S Hardikar, M Sato, RJ Galvin, AL Glasebrook and JD Termine
Endocrine Research, Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, Indiana 46285, USA.

Estrogen or raloxifene (LY156758) prevent estrogen deficiency-induced bone loss in animals and humans. We demonstrated in the rat that a 22% reduction in bone mineral density generated by ovariectomy was associated with a 2-fold reduction of transforming growth factor-beta 3 (TGF beta 3) messenger RNA expression in the femur. Administration of 17 beta-estradiol or raloxifene to ovariectomized rats restored both bone mineral density and TGF beta 3 messenger RNA expression in the femur to levels measured in intact animals. In transient transfection assays, the promoter sequence from -38 to + 110 of the human TGF beta 3 gene, which contains no palindromic estrogen response element, was sufficient to mediate 17 beta-estradiol or raloxifene induced-reporter gene expression in presence of the estrogen receptor. Raloxifene activated TGF beta 3 promoter as a full agonist at nanomolar concentrations. In the same cellular system, raloxifene inhibited the estrogen response element-containing vitellogenin promoter expression as a pure estrogen antagonist. In two well characterized osteoclast differentiation models, TGF beta 3 significantly inhibited the differentiation and bone-resorptive activities of murine and avian osteoclasts. These findings suggest that regulation of TGF beta 3 gene expression by raloxifene or estrogen in bone may be an important target to mediate bone maintenance.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M.-C. Aubin, C. Lajoie, R. Clement, H. Gosselin, A. Calderone, and L. P. Perrault
Female Rats Fed a High-Fat Diet Were Associated with Vascular Dysfunction and Cardiac Fibrosis in the Absence of Overt Obesity and Hyperlipidemia: Therapeutic Potential of Resveratrol
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 961 - 968.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
C K Wang, R S Robinson, A P F Flint, and G E Mann
Quantitative analysis of changes in endometrial gland morphology during the bovine oestrous cycle and their association with progesterone levels
Reproduction, August 1, 2007; 134(2): 365 - 371.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Mao, V. Paharkova-Vatchkova, J. Hardy, M. M. Miller, and S. Kovats
Estrogen Selectively Promotes the Differentiation of Dendritic Cells with Characteristics of Langerhans Cells
J. Immunol., October 15, 2005; 175(8): 5146 - 5151.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Rendi, N. Suh, W. W. Lamph, S. Krajewski, J. C. Reed, R. A. Heyman, A. Berchuck, K. Liby, R. Risingsong, D. B. Royce, et al.
The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor {beta}-Dependent Apoptosis in Breast Cancer
Cancer Res., May 15, 2004; 64(10): 3566 - 3571.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. J. Grainger
Transforming Growth Factor {beta} and Atherosclerosis: So Far, So Good for the Protective Cytokine Hypothesis
Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 399 - 404.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Viereck, C. Grundker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.-H. Frosch, D. Raddatz, G. Emons, and L. C. Hofbauer
Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4206 - 4213.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Zhou, G. Turgeman, S. E. Harris, D. C. Leitman, B. S. Komm, P. V. N. Bodine, and D. Gazit
Estrogens Activate Bone Morphogenetic Protein-2 Gene Transcription in Mouse Mesenchymal Stem Cells
Mol. Endocrinol., January 1, 2003; 17(1): 56 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz
Changes in Proinflammatory Cytokine Activity after Menopause
Endocr. Rev., February 1, 2002; 23(1): 90 - 119.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. C. Rodriguez, N. P. Nagarsheth, K. L. Lee, R. C. Bentley, D. K. Walmer, M. Cline, R. S. Whitaker, P. Isner, A. Berchuck, R. K. Dodge, et al.
Progestin-Induced Apoptosis in the Macaque Ovarian Epithelium: Differential Regulation of Transforming Growth Factor-{beta}
J Natl Cancer Inst, January 2, 2002; 94(1): 50 - 60.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Lu and V. Giguere
Requirement of Ras-Dependent Pathways for Activation of the Transforming Growth Factor {beta}3 Promoter by Estradiol
Endocrinology, February 1, 2001; 142(2): 751 - 759.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
J. E. Compston
Sex Steroids and Bone
Physiol Rev, January 1, 2001; 81(1): 419 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. E. Nuttall, G. B. Stroup, P. W. Fisher, D. P. Nadeau, M. Gowen, and L. J. Suva
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells
Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1550 - C1557.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. S. Jones, E. Parrott, and I. N. H. White
Activation of Transcription by Estrogen Receptor alpha and beta Is Cell Type- and Promoter-dependent
J. Biol. Chem., November 5, 1999; 274(45): 32008 - 32014.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
S. Kimmins and L. A. MacLaren
Cyclic Modulation of Integrin Expression in Bovine Endometrium
Biol Reprod, November 1, 1999; 61(5): 1267 - 1274.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
V. C. Jordan and M. Morrow
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
Endocr. Rev., June 1, 1999; 20(3): 253 - 278.
[Abstract] [Full Text]

Home page
 J. Appl. Physiol.Home page
R. T. Turner, L. S. Kidder, M. Zhang, S. A. Harris, K. C. Westerlind, A. Maran, and T. J. Wronski
Estrogen has rapid tissue-specific effects on rat bone
J Appl Physiol, June 1, 1999; 86(6): 1950 - 1958.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
S. M. Thacher, S. Nagpal, E. S. Klein, T. Arefieg, G. Krasinski, D. DiSepio, C. Agarwal, A. Johnson, R. L. Eckert, and R. A. S. Chandraratna
Cell Type and Gene-specific Activity of the Retinoid Inverse Agonist AGN 193109: Divergent Effects from Agonist at Retinoic Acid Receptor {{gamma}} in Human Keratinocytes
Cell Growth Differ., April 1, 1999; 10(4): 255 - 262.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J. Pellaud, U. Schote, T. Arvinte, and J. Seelig
Conformation and Self-association of Human Recombinant Transforming Growth Factor-beta 3 in Aqueous Solutions
J. Biol. Chem., March 19, 1999; 274(12): 7699 - 7704.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
W. Khovidhunkit and D. M. Shoback
Clinical Effects of Raloxifene Hydrochloride in Women
Ann Intern Med, March 2, 1999; 130(5): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
S. W. Lamberts, A. W. van den Beld, and A. van der Lely
The Endocrinology of Aging
Science, October 17, 1997; 278(5337): 419 - 424.
[Abstract] [Full Text]

Home page
 ScienceHome page
K. Paech, P. Webb, G. G. Kuiper, S. Nilsson, J. Gustafsson, P. J. Kushner, and T. S. Scanlan
Differential Ligand Activation of Estrogen Receptors ERalpha and ERbeta at AP1 Sites
Science, September 5, 1997; 277(5331): 1508 - 1510.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
T. M. Willson, J. D. Norris, B. L. Wagner, I. Asplin, P. Baer, H. R. Brown, S. A. Jones, B. Henke, H. Sauls, S. Wolfe, et al.
Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone
Endocrinology, September 1, 1997; 138(9): 3901 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. A. Zajchowski, K. Kauser, D. Zhu, L. Webster, S. Aberle, F. A. White III, H.-L. Liu, R. Humm, J. MacRobbie, P. Ponte, et al.
Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints
J. Biol. Chem., May 19, 2000; 275(21): 15885 - 15894.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society